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Summary: The aim of this study was to assess the eﬃcacy of a
solution composed by verbascoside, polyvinylpyrrolidone, and
sodium hyaluronate (Mucosyte) in the treatment of chemotherapy-
induced oral mucositi (OM). Patients between 5 and 18 years
receiving chemotherapy for acute lymphoblastic leukemia and with
OM grade 1 or 2 were randomized in group A (treated with
Mucosyte, 3 mouthwashes/d per 8 d) and group B (treated with
placebo, ie, an inert water-based solution, 3 mouthwashes/d per
8 d). The OM scoring was performed at day 1 (diagnosis of OM-
T0), after 3 days of treatment (T1), and at day 8 (T2). Pain was
evaluated through the visual analog scale with the same timing of
OM measurement. A total of 56 patients were included (28 patients
per group). Group A experienced a statistically significant decline
of OM at T2 (P=0.0038); a statistically significant diﬀerence in
pain reduction between 2 groups both at T1 and at T2 (P<0.005)
was observed. The use of Mucosyte mouthwashes in children with
chemotherapy-induced OM may be recommended as supportive
therapy.
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Oral mucositis (OM) is a common side eﬀect of chemo-therapy, especially in case of hematopoietic stem cell
transplantation, due to the high-dose myeloablative chemo-
therapy used for conditioning regimens.1 The incidence of
OM in the pediatric population varies from 50% up to
80%.2,3 Mucositis significantly aﬀects the quality of life in
terms of pain, ability to eat, swallow, and talk; indeed,
symptoms are often of such severity as to require an inter-
ruption or curtailment of therapy. In the presence of neu-
tropenia, mucositis predisposes to septicemia, bacteremia, and
fungemia. Moreover, the presence of OM, lengthening the
hospitalization timing, is an important driver of health care
costs.4 Treatment guidelines for OM were issued in 2004 and
were recently updated by the Multinational Association of
Supportive Care in Cancer and International Society for Oral
Oncology (MASCC/ISOO). Current management of OM
might comprise growth factors and cytokines, anti-
inflammatory agents, anesthetics, analgesics, antimicrobial
and coating agents, cryotherapy, and mucosal protectants.5–7
Although several preventive and therapeutic approaches have
been evaluated, no single agent has been found to be superior.
Given the side eﬀects of pharmaceutical agents, comple-
mentary therapies are increasingly being used all over the
world to especially support OM-low grade. In recent years,
more attention has been focused on the role of natural drugs.8
These “natural substances” are low-molecular weight organic
compounds found in plants that activate a defence system
against physiological and/or environmental stress.9–11 Such
compounds have antioxidant, antimicrobial, and immuno-
modulatory properties and derive from secondary metabo-
lites, which belong mainly to the category of terpenes, terpe-
noids, alkaloids, phenols, and flavonoids.12–14 Polyphenols
compound are secondary metabolites widely distributed in the
plant kingdom, with many biological properties, antiallergic,
antiatherogenic, anti-inflammatory, antimicrobial, and anti-
oxidant.15 Of particular interest, in recent years, are the phe-
nylpropanoid glycosides (also synonymous with phenyl-
ethanoid glycosides) which are water-soluble derivatives of
phenylpropanoids, a large group of natural polyphenols.16
Verbascoside, a polyphenol present in many plants used for
food, flavouring, and medicines like olive and mullein,
shows the highest scavenger activity among phenyl-
propanoid glycosides tested, as well as a high antioxidant
power, even in comparison with other natural phenolic
compounds.17,18 In fact, it inhibits and blocks proin-
flammatory enzymes activity, especially of inducible nitric
oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).19
Recent studies have indicated that the fundamental
mechanisms involved in the pathogenesis of mucositis are
much more complex than direct damage to epithelium
alone. Chemotherapy induces cellular damage resulting in
death of the basal epithelial cells. The generation of reactive
oxygen species is believed to exert a role in the initiation of
mucosal injury.6
The aim of this study was to assess the eﬃcacy of a
solution composed by verbascoside, polyvinylpyrrolidone
(PVP), and sodium hyaluronate (Mucosyte; Biopharm,
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Paediatric Oncology Unit of Spedali Civili of Brescia
(Italy). Consecutive patients receiving chemotherapy for
acute lymphoblastic leukemia (ALL) (elaborate on the 2009
standard protocol) and with OM grade 1 or 2 were con-
sidered eligible for this study.
Enrolment criteria were: patients aged between 5 and
18 years with ALL undergoing any 1 of the phases of the
chemotherapy protocol and with OM grade 1 or 2. Exclu-
sion criteria were: OM grade >2, other hematologic
malignancies than ALL, hypersensitivity or allergy to any
of the components included in the study; radiotherapy;
antibiotic and antifungal drugs assumption. Age, sex, oral
hygiene grade, and absolute neutrophil count (ANC) were
recorded for each patient.
Study Design
This study was designed as a double-blinded placebo-
controlled study. Patients were randomized by the com-
puter code in 2 groups: group A treated with Mucosyte
(Biopharm) rinses and group B treated with placebo (ie, an
inert water-based solution). The 2 products were identical
regarding packaging and texture, identified only by a color
label. Patients were instructed to rinse with 15mL of sol-
ution (Mucosyte or placebo) for 2 minutes 3 times per day
for 8 days.
Randomization was performed using an automatically
generated list in a 1:1 block size for 2 patients. Patients
included in the study were randomly assigned to 1 of the 2
treatments. Patients received a number after inclusion,
corresponding to a color-coded mouth rinse (red for
Mucosyte and blue for placebo). The list and the colored
bottles were provided by the statistic while the clinical
researchers made the assignation of numbers in consecutive
order. Color codes were not opened until the end of the
study. Both patients and researchers were blinded
throughout the study.
OM Scoring
OM grade was scored by the same 2 pediatric dentists
blind to the randomized allocation, according to the
Common Toxicity Criteria Scale of the WHO. Lesions were
classified as grade 0=none; grade 1=soreness and
erythema; grade 2=erythema and ulcers without diﬃ-
culties in swallowing solid food; grade 3=ulcers requiring
only a liquid diet, and grade 4= introduction of parental
nutrition.
Oral examination and OM scoring were performed at
day 1 (diagnosis of OM) (T0), after 3 days of treatment (T1)
and at day 8 (T2).
PAIN Scoring
Pain was evaluated through the visual analog scale
(VAS) at the same timing of OM scoring. In this system, 1
indicates no pain and 10 indicates severe pain; patients were
asked to select a number from 1 to 10 on a ruler with drawn
faces to express the intensity of their pain (Wong Baker face
scale). Request of additional analgesia, which means the
number of times that children required pharmacological
support, was also recorded.
Oral Hygiene
Clinical assessment of oral hygiene status was per-
formed according to criteria of simplified oral hygiene index
(OHI-s) by Greene and Vermillion20 with a mouth mirror
and explorer.
Statistical Analysis
Statistical analysis was descriptive, including mean,
SD, and percentiles for variables as sex, age, and
localization.
To compare the 2 groups, we analyzed the data on sex
and disease as frequencies and percentages. Concordance or
diﬀerences in the frequency distribution between the 2
groups were tested using Student t test. A level of sig-
nificance of 5% was used and data were analyzed using
Stata software for Mac. The diﬀerences in decline of OM
and VAS score were analysed using Wilcoxon rank sum
test. The diﬀerence of the mean of the OHI-s and ANC at
T0 and T2 was evaluated using 2 ways analysis of variance.
Taking the hypothesis that there is a success percent-
age of 80% at day 8 for the group treated by Mucosyte
rinses and 40% for control group, the minimum number of
patients for the study, assuming a=0.05 and b=0.20
(study power=80%), has been calculated to be 55 (at least
23 per group).
Ethical Considerations
The study was planned and carried out in compliance
with the Declaration of Helsinki and Good Clinical Prac-
tice. All patients and their caregivers were informed about
the research and signed an Institutional review board-
approved informed consent.
RESULTS
A total of 59 patients were included in the study
according to the enrolment criteria. Three were excluded
because caregivers did not sign the informed consent.
Group A (Mucosyte) was composed by 28 children (19
female and 9 male, mean age 7±1.8) and group B (pla-
cebo) by 28 children (15 female and13 male, mean age
8±2.7).
OM Grading
OM appeared at a mean of 6.1 days after chemo-
therapy (range, 4 to 8 d).
At T0, the median of OM grading was 2 for group A
and 2 for group B (P>0.05). At the third day (T1), OM
grading median was 1 for group A and 2 for group B
(P=0.65); after 8 days (T2), OM grading median resulted
0 in group A and 1 in group B (P=0.038). Group A
experienced a statistically significative decline of OM just at
T2 (P=0.0038) (Fig. 1).
Pain Evaluation
The medians of VAS at the 3 intervals and P-values
obtained by Wilcoxon rank sum test are displayed
in Table 1. A statistically significative diﬀerence in pain
reduction between 2 groups both at T1 and at T2 (P<0.05)
was observed. During the study period, children treated by
Mucosyte rinses required less additional analgesia (para-
cetamol, tramadol, or morphine) with respect to those
belonging to the control group (P<0.05).
Oral Hygiene and ANC
The mean of OHI-S at T0 and T2 in both groups was
not statistically diﬀerent (P=0.15).
The mean of ANC at T0 and T2 in both groups was
not statistically diﬀerent (P=0.63).
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DISCUSSION
OM can aggravate the pediatric patients’ clinical
condition and elicit multiple debilitating oral symptoms
that irrevocably alter patients’ quality of life.2
The pathogenesis of chemotherapy-induced OM
appears to be related to oxidative stress induced by the
treatment. The reactive oxygen species cause direct and
indirect damage through transcription factors, such as
nuclear factor-kB, that activates iNOS, and the activator
protein-1, which induce the production of proinflammatory
cytokines, such as tumor necrosis factor and interleukin-
6.21,22
This pilot study was designed to investigate the eﬃcacy
of a solution, containing sodium hyaluronate, PVP, and
verbascoside, in chemotherapy-induced OM. Verbascoside
is the extract of syring vulgaris and it belongs to the fenil-
propanoid family, a new class of anti-inflammatory drugs.
Previous studies have suggested that verbascoside can
prevent the oxidative stress as it reduces the production
of superoxide radicals and consequently reduces the activity
of iNOS and COX-2 [23]. Moreover, it is involved in
controlling transforming growth factor beta-activated kin-
ase, a novel protein that mediates proinflammatory sig-
naling through induction of the transcription factor acti-
vator protein -1. Verbascoside induces the dose-dependent
decrease of the expression of interleukin-8, inhibiting
proinflammatory activity of enzymes like COX-2 and
iNOS, showing a cortison-like activity.14,23 Recent studies
have demonstrated that sodium hyaluronate accelerates
healing24 and helps to manage pain25 in patients with OM.
Some authors stated that the compound acts as a physical
barrier between the oral environment and oral mucosa,
inducing also biomolecular and physiological changes in
keratinocytes and mesenchimal cells.26,27
The severity of OM is mainly determined by the
type(s) and dose of cancer therapeutic agents used. The
therapeutic trend of combining diﬀerent chemotherapeutic
drugs further intensifies the likelihood of mucositis.28 To
exclude possible confounding factors, we selected patients
with ALL, undergoing the same chemotherapy protocol
(ALL 2009 standard protocol), which inter alia induces a
less deep and shorter aplasia.29 Instead, we did not consider
the treatment stage as a variable (to evaluate the eﬃcacy of
the mouthwash) because there are still no studies that
correlate OM (in terms of “duration” and “rate of healing”)
with the stage of treatment that caused it.
Moreover, we took into account only OM grade 1 or
2, usually requiring only topical therapy, not combined
with other device or drugs (ie, laser therapy, grow factors,
steroids). As regards the diagnosis of OM, a concomitant
herpes simplex virus infection—which is a known risk fac-
tor for aggravation of the severity of OM30—was excluded
because all patients underwent an antiviral prophylaxis
(5mg/kg/dose 3 times a day).
The results of this investigation suggest clinical bene-
fits in the use of the tested solution. According to our
results, OM significantly reduces in the study group respect
to the control group in 8 days. Also the pain, already after 3
days, is significantly decreased both from VAS results and
from the request of additional analgesia. The benefit may
depend on the synergic action of active components. The
mucoadhesive properties of PVP allow the continuous
release of sodium hyaluronate, which favors re-
epithelization and wound healing, and of verbascoside,
which has an anti-inflammatory action.
To exclude other confounding factors, we considered
also the oral hygiene grade and the ANC. The grade of oral
hygiene can aﬀect the incidence and severity of mucositis.
Maintenance of good and intensified oral hygiene is a
fundamental component of basic oral care.31 When oral
hygiene is compromised, gingival and mucosal inflamma-
tion caused by oral bacteria increases the risk of OM up to
bacteremia.32–34 According to our results, the grade of oral
hygiene was not statistically diﬀerent in the 2 groups. This
result was expected due to the strict oral hygiene protocols
to which oncohematological patients are subjected
according to the international guidelines.5,6,31
ANC was recorded because a decrease in the neu-
trophil count may result in an impaired ability to protect
against oral mucosal damage and may aﬀect the pro-
liferation of oral epithelial cells. Neutropenic patients are at
increased risk for microbial colonization of damaged
mucosal surfaces, resulting in increased proinflammatory
cytokines in oral mucosa, which may aggravate OM.2,35,36
The ANC was similar in the 2 groups and ranged
between 0.2"10(9) and 0.5"10(9)/L. So, even if the
patients with OM tended to be neutropenic, these data did
not aﬀect the outcome of the study. The results of this pilot
study should be interpreted with caution. Even if we tried to
exclude confounding factors, one limitation was the small
sample size. Within this limit, we can conclude that the use
of Mucosyte may lead to improvements in clinical param-
eters in children with chemotherapy-induced low-grade OM










FIGURE 1. Results for decline in oral mucositis grade at T0, T1,
and T2 in the group A and B. T0 indicates diagnosis of oral
mucositis on day 1; T1, after 3 days of treatment; T2, at day 8.
TABLE 1. Results for Decline in Visual Analog Scale at T0, T1, and
T2 in the Group A and in the Group B
Group A Group B W (Wilcoxon test) P
T0 4 4 3805.5 0.90
T1 1 2 3252 0.002*
T2 0 1 3160.5 0.0005*
Medians, Wilcoxon rank sum test and P-value. Test: Wilcoxon rank sum
test.
T0 indicates diagnosis of oral mucositis on day 1; T1, after 3 days of
treatment; T2, at day 8.
*P <0.05.
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